Nanbu County People's Hospital Successfully Completes One of China's First RhythPulse® PFA Pulse Field Ablation Procedures Using XuanYu Medical's Innovative System
ShineyoMedical
Provider of Atrial Fibrillation Electrophysiology and Peripheral Vascular Intervention Solutions
Click the blue words to follow us
ENTERPRISE
Recently, the Cardiology Department of Nanbu People's Hospital, under the leadership of Deputy Director Li Zhiming, successfully completed one of the first batch of RhythPulse procedures in China, produced by ShineyoMedical.®-PFA Pulsed Field Ablation One-Stop Surgery.Further validates the comprehensive advantages of PFA technology in terms of effectiveness, safety, and efficiency; marking that China's independently developed PFA technology is developing comprehensively in cultural continuity, providing patients suffering from atrial fibrillation with a safer and more efficient new treatment option.
Patient Information
Elderly female, 66 years old, admitted to the hospital with "paroxysmal palpitations for 1 year", diagnosed with: paroxysmal atrial fibrillation (CHA2DS2-VASc score 3; HAS-BLED score 3). After comprehensive preoperative evaluation, valvular heart disease was ruled out, no left atrial thrombus was found, and the patient met the indications for pulsed electric field ablation of atrial fibrillation. After full communication with the patient and her family, it was decided to useShineyoMedical RhythPulse®PFA Pulsed Electric Field AblationTreat the patient.
Surgical Procedure
The patient was placed in a supine position, routinely disinfected, and draped. The puncture site was locally anesthetized with 2% lidocaine. After two attempts at puncturing the right femoral vein, a coronary sinus electrode was inserted. Following successful transseptal puncture, contrast agent was injected to confirm that the puncture needle was located in the left atrium. Heparin was administered systemically, and under the guidance of a three-dimensional mapping system, modeling of the left atrium and pulmonary veins was performed. Under analgesic sedation with sufentanil combined with midazolam, pulsed-field ablation was conducted for bilateral pulmonary vein electrical isolation. During the isolation of the posterior wall of the right pulmonary vein, atrial fibrillation converted to sinus rhythm. Bilateral pulmonary vein electrical isolation was completed, and both atrial input and pulmonary vein output block were verified.
Left Atrial Substrate Map
Atrial Fibrillation Converted to Sinus Rhythm
Left Atrial Ablation Pathway
Expert Profile
Li Zhiming
Master of Medicine, Associate Chief Physician, Deputy Director of the Department of Cardiology
Successively studied at Zhongshan Hospital of Fudan University, West China Hospital of Sichuan University, and other medical centers. Obtained the interventional qualification for radiofrequency ablation of arrhythmia and pacemaker implantation from the Chinese Medical Doctor Association. Committee member of the Arrhythmia Branch of the Sichuan Medical Promotion Association, committee member of the Nanchong Cardiovascular Specialty Committee, and standing committee member of the Nanchong Pacemaker and Electrophysiology Specialty Committee. Engaged in clinical, research, and teaching work in cardiology for over 10 years, specializing in interventional treatment of cardiovascular diseases (catheter ablation for atrial fibrillation, atrial flutter, supraventricular tachycardia, etc., left atrial appendage closure, permanent pacemaker implantation, ICD, and CRT implantation). Presided over one research project of the Sichuan Provincial Department of Education and published three SCI papers.
END
【ShineyoMedical RhythPulse®-PFA System】
ShineyoMedical's RhythPulse®-PFA System is the first approved Pulse Field Ablation (PFA) system in China that integrates multi-channel, large focal points, and targeted ablation, primarily used for treating drug-refractory and recurrent atrial fibrillation as well as other forms of rapid arrhythmia. Its core advantages include:
Large Focal Design:Using the world's first 10mm ring ablation catheter, a single discharge can cover a lesion area with a diameter of 10mm, increasing the ablation efficiency more than three times compared to traditional technology.
Targeted Ablation Technology:Equipped with an intelligent proximity detection module, it monitors the contact status between the electrode and myocardial tissue in real time, reducing the risk of hemolysis caused by ineffective discharges, and decreasing postoperative plasma free hemoglobin content by 50%.
Excellent Clinical Validation:In a clinical trial involving 151 cases, the immediate success rate was 100%, and the success rate for atrial fibrillation treatment at 12 months post-operation reached 85.07%, meeting internationally leading standards.
